SPC 104065
Latest Information Update: 14 Mar 2008
Price :
$50 *
At a glance
- Originator Research Triangle Park Laboratories
- Class Antineoplastics
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Nov 1995 Preclinical development for Cancer in USA (unspecified route)